Oxford drug discovery spin-out secures funding
22 Jan 2019 by qmwwwtqmqt.d qmwwwtqmqt.d
Oxford University biotech spinout OMass Therapeutics has secured £14 million in its Series A funding round.
The investment will support OMass’ efforts to develop structural mass spectronomy technology, used to study intact protein assemblies that could uncover potential drugs for unmet medical needs.
Professor Dame Carol Robinson, Founder & Scientific Advisor at OMass Therapeutics, said: “It is very exciting for me to see the company take this new direction following Syncona investment. Having devoted my career to developing these mass spectrometry approaches I am now looking forward to demonstrating just how powerful they can be.”
The funding round was led by Syncona, the life sciences investment arm of the Wellcome Trust. It is the second investment by Syncona into an Oxford University spinout; the first, Nightstar Therapeutics – a gene therapy company that specialises in treatments for inherited retinal diseases – went from spin out to IPO in four years.
Oxford Sciences Innovation also participated in the round.
